Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2023 Net Income-$1.23M-$1.23MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,124,740N/M Operating Cash Flowderived-$247,170N/M ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end